Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

New drug for multiple myeloma could be available within next few months in Europe

The International Myeloma Foundation - improving the quality of life of myeloma patients while working toward prevention and a cure - today said the newest drug for treating multiple myeloma could be available to patients in Europe within the next few months.

1 Jun 2013

Takeda begins MLN9708 phase 3 clinical trial in newly diagnosed myeloma patients

Takeda Pharmaceutical Company Limited today announced the initiation of an international phase 3 clinical trial evaluating once a week MLN9708 in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are not candidates for transplant.

24 May 2013

UC Irvine chemists create new method to identify clinically usable markers for prostate cancer in urine

Early screening for prostate cancer could become as easy for men as personal pregnancy testing is for women, thanks to UC Irvine research published today in the Journal of the American Chemical Society.

23 May 2013

Depressive symptoms linked to early death in cancer survivors

Depressed cancer survivors are twice as likely to die prematurely than those who do not suffer from depression, irrespective of the cancer site. That's according to a new study, by Floortje Mols and colleagues, from Tilburg University in The Netherlands.

17 May 2013

Loyola opens 20-bed unit for patients undergoing stem cell transplants for cancers

Loyola University Medical Center has opened a new 20-bed unit for patients undergoing stem cell transplants for cancers such as leukemia, lymphoma and multiple myeloma.

9 May 2013

Entremed reports patent issuance for its lead drug candidate ENMD-2076

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, today announced the issuance by the Chinese State Intellectual Property Office of Patent Certificate No. ZL 200680044656.7.

7 May 2013

Single antibody could be key to treating multiple myeloma

A single antibody could be the key to treating multiple myeloma, or cancer of the blood, currently without cure or long-term treatment.

6 May 2013

EntreMed announces issuance of patent for clinical-stage compound, 2-methoxyestradiol

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced the issuance of a U.S. patent covering methods of treatment and formulations for its clinical-stage compound, 2-methoxyestradiol.

3 May 2013

Researchers identify how proteasome takes care of unwanted, potentially toxic proteins

Proteins, unlike diamonds, aren't forever. And when they wear out, they need to be degraded in the cell back into amino acids, where they will be recycled into new proteins.

29 Apr 2013

Senesco completes cohort 2 in Phase 1b/2a clinical study of SNS01-T

Senesco Technologies, Inc. reported today that it has completed cohort 2 in its Phase 1b/2a clinical study of SNS01-T.

23 Apr 2013

BioInvent starts BI-505 phase II study in patients with smoldering multiple myeloma

BioInvent International announced today that the first patient has been treated in a phase II study of the drug candidate BI-505, developed for the treatment of multiple myeloma.

23 Apr 2013

Enrollment for Pharmacyclics' Phase III study using ibrutinib in CLL patients completed

Pharmacyclics, Inc. announced today that the enrollment target of 350 patients for its Phase III study using ibrutinib monotherapy versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia / small lymphocytic lymphoma, (RESONATE) was achieved on April 3, 2013.

23 Apr 2013

New pre-clinical study suggests novel drug combination therapy for leukemia treatment

A new, pre-clinical study by researchers at Virginia Commonwealth University Massey Cancer Center suggests that a novel drug combination could lead to profound leukemia cell death by disrupting the function of two major pro-survival proteins.

18 Apr 2013

Preclinical data on anti-cancer activity of BI-505 published online in Cancer Cell

BioInvent International AB, a biotech company developing novel antibody therapeutics for treatment of cancer, today announced that the April 15, 2013 online issue of the highly prestigious cancer research journal Cancer Cell features a data publication demonstrating potent anti-cancer activity of BI-505 in multiple preclinical myeloma tumor models.

17 Apr 2013

$Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients$

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.

11 Apr 2013

BioLineRx gets regulatory approvals in US to start BL-8040 Phase IIa trial for treatment of AML

BioLineRx, a biopharmaceutical development company, announced today that it has received all necessary regulatory approvals in the US to commence a Phase IIa trial for BL-8040, for the treatment of Acute Myeloid Leukemia.

11 Apr 2013

Study: Chicken-killing virus is a promising treatment for prostate cancer

A study at the Virginia-Maryland Regional College of Veterinary Medicine has identified a chicken-killing virus as a promising treatment for prostate cancer in humans.

9 Apr 2013

FDA grants Breakthrough Therapy Designation for ibrutinib as monotherapy for CLL patients

Pharmacyclics, Inc. announced today that the U.S. Food and Drug Administration has granted an additional Breakthrough Therapy Designation for the investigational oral agent ibrutinib as monotherapy for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma patients with deletion of the short arm of chromosome 17 (deletion 17p).

8 Apr 2013

BioInvent International presents clinical results of BI-505 at myeloma workshop in Kyoto

BioInvent International AB announce that the previously communicated positive results from a phase I trial of BI-505 is presented today at The International Myeloma Workshop in Kyoto, Japan.

4 Apr 2013

TGen to present scientific benefits of whole genome sequencing at myeloma workshop

The scientific benefits of whole genome sequencing at the Translational Genomics Research Institute will be presented at the 14th International Myeloma Workshop, April 3-7 at the Kyoto International Conference Center.

4 Apr 2013

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

New drug for multiple myeloma could be available within next few months in Europe

Takeda begins MLN9708 phase 3 clinical trial in newly diagnosed myeloma patients

UC Irvine chemists create new method to identify clinically usable markers for prostate cancer in urine

Depressive symptoms linked to early death in cancer survivors

Loyola opens 20-bed unit for patients undergoing stem cell transplants for cancers

Entremed reports patent issuance for its lead drug candidate ENMD-2076

Single antibody could be key to treating multiple myeloma

EntreMed announces issuance of patent for clinical-stage compound, 2-methoxyestradiol

Researchers identify how proteasome takes care of unwanted, potentially toxic proteins

Senesco completes cohort 2 in Phase 1b/2a clinical study of SNS01-T

BioInvent starts BI-505 phase II study in patients with smoldering multiple myeloma

Enrollment for Pharmacyclics' Phase III study using ibrutinib in CLL patients completed

New pre-clinical study suggests novel drug combination therapy for leukemia treatment

Preclinical data on anti-cancer activity of BI-505 published online in Cancer Cell

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

BioLineRx gets regulatory approvals in US to start BL-8040 Phase IIa trial for treatment of AML

Study: Chicken-killing virus is a promising treatment for prostate cancer

FDA grants Breakthrough Therapy Designation for ibrutinib as monotherapy for CLL patients

BioInvent International presents clinical results of BI-505 at myeloma workshop in Kyoto

TGen to present scientific benefits of whole genome sequencing at myeloma workshop

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in